Craig JW, Mina MJ, Crombie JL, et al. Assessment of CD52 expression in "double-hit" and "double-expressor" lymphomas: Implications for clinical trial eligibility. PLoS One. 2018;13(7):e0199708. doi:10.1371/journal.pone.0199708PubMedDOIGoogle Scholar
Hoover P, Der E, Berthier CC, et al. Accelerating Medicines Partnership: Organizational Structure and Preliminary Data From the Phase 1 Studies of Lupus Nephritis. Arthritis Care Res (Hoboken). 2020;72(2):233-242. doi:10.1002/acr.24066PubMedDOIGoogle Scholar
Eismann J, Heng YJ, Waldschmidt JM, et al. Transcriptome analysis reveals overlap in fusion genes in a phase I clinical cohort of TNBC and HGSOC patients treated with buparlisib and olaparib. J Cancer Res Clin Oncol. 2020;146(2):503-514. doi:10.1007/s00432-019-03078-9PubMedDOIGoogle Scholar